LEDIPASVIR\SOFOSBUVIR: 23,616 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
23,616
Total FAERS Reports
1,371 (5.8%)
Deaths Reported
4,031
Hospitalizations
23,616
As Primary/Secondary Suspect
384
Life-Threatening
303
Disabilities
First Report: 1970 · Latest Report: 20241027
What Are the Most Common LEDIPASVIR\SOFOSBUVIR Side Effects?
#1 Most Reported
Fatigue
4,609 reports (19.5%)
#2 Most Reported
Headache
4,203 reports (17.8%)
#3 Most Reported
Nausea
1,471 reports (6.2%)
All LEDIPASVIR\SOFOSBUVIR Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 4,609 | 19.5% | 38 | 205 |
| Headache | 4,203 | 17.8% | 24 | 222 |
| Nausea | 1,471 | 6.2% | 31 | 167 |
| Drug ineffective | 1,397 | 5.9% | 31 | 87 |
| Hepatitis c | 1,076 | 4.6% | 23 | 81 |
| Diarrhoea | 1,065 | 4.5% | 39 | 134 |
| Insomnia | 1,021 | 4.3% | 14 | 95 |
| Hepatocellular carcinoma | 640 | 2.7% | 76 | 136 |
| Vomiting | 623 | 2.6% | 44 | 208 |
| Dizziness | 604 | 2.6% | 21 | 140 |
| Asthenia | 558 | 2.4% | 43 | 173 |
| Drug dose omission | 553 | 2.3% | 5 | 140 |
| Treatment failure | 511 | 2.2% | 6 | 20 |
| Death | 471 | 2.0% | 470 | 65 |
| Arthralgia | 407 | 1.7% | 3 | 37 |
| Dyspnoea | 405 | 1.7% | 26 | 171 |
| Rash | 402 | 1.7% | 6 | 26 |
| Constipation | 389 | 1.7% | 11 | 49 |
| Anaemia | 384 | 1.6% | 57 | 163 |
| Pain | 372 | 1.6% | 6 | 66 |
Who Reports LEDIPASVIR\SOFOSBUVIR Side Effects? Age & Gender Data
Gender: 42.9% female, 57.1% male. Average age: 57.9 years. Most reports from: US. View detailed demographics →
Is LEDIPASVIR\SOFOSBUVIR Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 1 | 0 | 0 |
| 2002 | 2 | 0 | 1 |
| 2004 | 7 | 0 | 7 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 1 |
| 2008 | 2 | 0 | 0 |
| 2009 | 1 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 4 | 1 | 2 |
| 2013 | 8 | 0 | 1 |
| 2014 | 201 | 14 | 63 |
| 2015 | 3,247 | 260 | 1,146 |
| 2016 | 4,515 | 248 | 824 |
| 2017 | 3,878 | 140 | 422 |
| 2018 | 2,143 | 76 | 276 |
| 2019 | 1,040 | 41 | 157 |
| 2020 | 266 | 20 | 47 |
| 2021 | 86 | 10 | 31 |
| 2022 | 35 | 3 | 14 |
| 2023 | 17 | 3 | 3 |
| 2024 | 6 | 2 | 0 |
What Is LEDIPASVIR\SOFOSBUVIR Used For?
| Indication | Reports |
|---|---|
| Hepatitis c | 8,924 |
| Chronic hepatitis c | 6,621 |
| Product used for unknown indication | 3,087 |
| Hepatic cirrhosis | 552 |
| Hepatitis c virus test positive | 116 |
| Hepatitis | 70 |
| Essential hypertension | 64 |
| Chronic hepatitis | 47 |
| Gastrooesophageal reflux disease | 44 |
| Hepatitis b | 43 |
LEDIPASVIR\SOFOSBUVIR vs Alternatives: Which Is Safer?
LEDIPASVIR\SOFOSBUVIR vs LEFLUNOMIDE
LEDIPASVIR\SOFOSBUVIR vs LEMBOREXANT
LEDIPASVIR\SOFOSBUVIR vs LENACAPAVIR
LEDIPASVIR\SOFOSBUVIR vs LENALIDOMIDE
LEDIPASVIR\SOFOSBUVIR vs LENIOLISIB
LEDIPASVIR\SOFOSBUVIR vs LENOGRASTIM
LEDIPASVIR\SOFOSBUVIR vs LENVATINIB
LEDIPASVIR\SOFOSBUVIR vs LEPONEX
LEDIPASVIR\SOFOSBUVIR vs LERCANIDIPINE
LEDIPASVIR\SOFOSBUVIR vs LETAIRIS
Official FDA Label for LEDIPASVIR\SOFOSBUVIR
Official prescribing information from the FDA-approved drug label.